<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2205233686
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1987
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRENTAL TAB 400MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PENTOXIFYLLINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        99.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="sanofi S.R.L" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            sanofi S.R.L
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C04AD03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Trental 400 mg is a medicine for the treatment of peripheral blood flow disorders.<br />Trental 400 mg prolonged-release tablets can be used for the following:<br />&ndash; to help patients with intermittent claudication (pain on walking) due to chronic peripheral<br />vascular disease in Fontaine stage II to walk for longer distances, if other treatments such as<br />physical therapy (gait training), blood vessel opening and/or blood vessel reconstruction cannot<br />be used or are not appropriate.<br />&ndash; as treatment for inner ear function disorders related to blood circulation problems (difficulty<br />hearing, sudden deafness, etc.).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Trental 400 mg if:<br />&ndash; you are allergic to the active substance pentoxifylline, other methylxanthines or any of the other<br />ingredients of this medicine (listed in Section 6),<br />&ndash; you have had an acute heart attack,<br />&ndash; you have bleeding in the brain or other relevant bleeding (increased risk of bleeding),<br />&ndash; you have stomach and/or intestinal ulcers,<br />&ndash; you have conditions involving an increased tendency to bleed,<br />&ndash; you have retinal bleeding (increased risk of bleeding).<br />If retinal bleeding occurs during treatment, Trental must be stopped immediately.<br />Warnings and precautions<br />At the first signs of an allergic reaction, Trental must be discontinued immediately and a doctor<br />informed.</p><p>Particularly careful medical monitoring is necessary in patients with heart rhythm disorders, low blood<br />pressure, narrowing of the coronary heart vessels, following a heart attack or after an operation.<br />Trental should be taken with particular care and under medical supervision in patients with certain<br />autoimmune diseases (systemic lupus erythematosus and mixed connective tissue diseases).<br />When Trental is used simultaneously with medicines that reduce blood clotting (oral anticoagulants,<br />vitamin K antagonists), careful medical supervision and frequent monitoring of coagulation values<br />(INR) are necessary because of the risk of bleeding.<br />Particularly close medical monitoring is required in:<br />&ndash; Patients treated simultaneously with Trental and oral blood sugar-lowering drugs or insulin,<br />&ndash; Patients treated simultaneously with Trental and ciprofloxacin (medicine for the treatment of<br />bacterial infections).<br />The blood count should be monitored regularly during treatment with Trental.<br />In patients with impaired kidney function (creatinine clearance less than 30 ml/min) or with severe<br />liver function disorders, elimination of pentoxifylline may be delayed. In such cases, a dose reduction<br />and appropriate monitoring are necessary (see also Section 3).<br />Children and adolescents<br />There is no experience with the use of Trental in children and adolescents.<br />Other medicines and Trental 400 mg<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines.<br />Blood pressure-lowering medicines (antihypertensives and drugs that may lower blood pressure)<br />Trental may enhance the effect of blood-pressure lowering medicines, and a greater drop in blood<br />pressure may occur.<br />Medicines that reduce blood clotting (anticoagulants)<br />Trental may increase the effect of anticoagulants. In patients with an increased tendency to bleed due<br />to simultaneous administration of anticoagulants, any bleeding that occurs may be exacerbated.<br />Furthermore, cases of increased inhibition of blood clotting have been reported in patients treated<br />simultaneously with Trental and vitamin K antagonists (coumarins). The anticoagulant effect must<br />therefore be closely monitored by the doctor in these patients (e.g. regular INR tests), particularly<br />when Trental treatment is started or when dosage is adjusted.<br />Oral antidiabetics (medicines for treating diabetes), insulin<br />An increase in the blood sugar-lowering effect of these medicines may occur (hypoglycemic<br />reactions). Blood sugar levels should be checked at intervals defined on a case-by-case basis.<br />Theophylline (medicine for treating respiratory diseases)<br />Increased levels of theophylline in the blood are possible and the side effects of theophylline may<br />therefore be enhanced during treatment of respiratory diseases.<br />Cimetidine (stomach acid-reducing medicine)<br />An increase in plasma pentoxifylline levels and an increased effect of Trental are possible.</p><p>Ciprofloxacin (medicine to treat bacterial infections)<br />Simultaneous use of Trental and ciprofloxacin may increase serum pentoxifylline concentrations in<br />some patients. Therefore, simultaneous use of these medicines may increase the number and severity<br />of side effects.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />your doctor for advice before taking this medicine.<br />Trental 400 mg should not be taken during pregnancy as there is insufficient experience in pregnant<br />women.<br />Pentoxifylline passes into breast milk, but the infant receives only extremely small quantities of the<br />active substance. Therefore, no effects on the infant are to be expected during breast-feeding when the<br />drug is used properly. Before Trental is used in breast-feeding women, a careful benefit-risk<br />assessment must be carried out by the doctor.<br />Driving and using machines<br />No effects on the ability to drive and use machines are known.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist<br />if you are not sure.<br />Intermittent claudication due to chronic peripheral arterial occlusive disease in Fontaine stage IIb<br />Unless prescribed otherwise by your doctor, take 1 Trental 400 mg prolonged-release tablet 3 times<br />daily (i.e. 1200 mg of pentoxifylline per day).<br />Functional disorders of the inner ear related to blood flow (difficulty hearing, sudden deafness, etc.)<br />Unless prescribed otherwise by your doctor, the usual dose is 1 Trental 400 mg prolonged-release<br />tablet 2 to 3 times daily (i.e. 800 to 1200 mg of pentoxifylline per day).<br />Low blood pressure or blood circulation disorders:<br />Specific dosage instructions may be necessary in patients with low blood pressure or blood circulation<br />disorders.<br />Impaired kidney function (creatinine clearance less than 30 ml/min)<br />The dose should be adjusted depending on individual tolerance in patients with impaired kidney<br />function.<br />Severe liver function disorders<br />A dose reduction is required in patients with severe liver impairment. Your doctor will determine the<br />reduced dose on an individual basis depending on the severity of the disorder and individual tolerance.<br />Method and duration of administration<br />Take the prolonged-release tablets whole after a meal with sufficient liquid (e.g. a glass of water).<br />Your doctor will determine the duration of treatment.<br />Note<br />In cases of accelerated gastrointestinal transit (laxative use, diarrhea, surgical shortening of the<br />intestine, etc.) patients have in very rare instances found tablet fragments in their feces If this occurs,<br />you should consult your doctor.</p><p>If you take more Trental 400 mg than you should<br />The following signs and symptoms may occur after accidental or intentional use of too much Trental<br />400 mg:<br />dizziness, nausea, fall in blood pressure, accelerated heart rate, redness of the face with a feeling of<br />heat (hot flush), loss of consciousness, fever, restlessness, absence of reflexes, tonic-clonic seizures,<br />coffee ground vomit and heart rhythm disorders.<br />In case of overdose, immediately inform a doctor or an emergency doctor, who will take any<br />necessary measures.<br />If you forget to take Trental 400 mg<br />If you forget to take a dose, do not take a double dose of Trental the next time. Continue treatment as<br />recommended in the dosage instructions or as prescribed by your doctor.<br />If you stop taking Trental 400 mg<br />You should not interrupt or stop treatment with Trental 400 mg without first talking to your doctor.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />The following categories are used for the frequency of side effects:<br />Very common: more than 1 in 10 treated patients<br />Common: 1 to 10 in 100 treated patients<br />Uncommon: 1 to 10 in 1 000 treated patients<br />Rare: 1 to 10 in 10 000 treated patients<br />Very rare: fewer than 1 in 10 000 treated patients<br />Unknown: frequency cannot be estimated based on available data<br />Possible side effects<br />Blood<br />Very rare: reduced blood platelet count with bleeding under the skin (thrombocytopenic purpura), and<br />in some cases, reduction or absence of formation of all blood cells.<br />Regular blood counts must therefore be performed.<br />Immune system/Allergic reactions<br />Uncommon: Allergic reactions of the skin (see skin effects).<br />Very rare: severe allergic reactions occurring within minutes of Trental administration such as<br />swelling of the skin and mucous membranes (angioedema), bronchospasm, circulatory failure<br />(anaphylactic shock).<br />At the first signs of an allergic reaction, Trental must be discontinued immediately and a doctor<br />informed.<br />Mental disorders<br />Uncommon: restlessness, sleep disorders.<br />Nervous system<br />Uncommon: dizziness, trembling, headache.</p><p>Very rare: feeling of numbness and coldness in the limbs (paresthesia), seizures (convulsions),<br />bleeding in the skull. Symptoms of a non-infection-related inflammation of the lining of the brain may<br />occur. Patients with autoimmune diseases (i.e. systemic lupus erythematosus or mixed connective<br />tissue diseases) appear particularly susceptible to this type of effect. In all cases, symptoms regressed<br />after Trental was stopped.<br />Eyes<br />Uncommon: visual disturbances,<br />conjunctivitis. Very rare: retinal bleeding,<br />retinal detachment.<br />If retinal bleeding occurs during treatment, Trental must be stopped immediately.<br />Heart<br />Uncommon: heart rhythm disorders such as accelerated heart beat.<br />Rare: feeling of tightness in the chest (angina pectoris), breathlessness.<br />Blood vessels<br />Common: redness of the face with a feeling of heat (hot flush).<br />Rare: bleeding (see side effects for various organs).<br />Digestive tract<br />Common: gastrointestinal disorders such as nausea, vomiting, feeling of fullness, heaviness in the<br />stomach, diarrhea.<br />Rare: stomach and intestinal bleeding.<br />Liver and gall bladder<br />Very rare: obstruction of bile fluid within the liver, increase in liver test values (see Investigations).<br />Skin<br />Uncommon: itching, redness of the skin, hives.<br />Rare: skin and mucous membrane bleeding.<br />Very rare: serious skin reactions (epidermal necrolysis, Stevens-Johnson syndrome), sweating.<br />Kidneys and urinary tract<br />Rare: bleeding in the area of the urinary and genital organs.<br />Investigations<br />Rare: reduced blood pressure.<br />Very rare: increased liver test values, increased blood pressure.<br />General disorders<br />Uncommon: fever.<br />Rare: Accumulation of fluid in tissues (e.g. in arms and legs).<br />Note<br />Breathlessness, vomiting, bouts of sweating and dizziness can be early signs of severe allergic<br />reactions. If any of these occur, stop Trental 400 mg immediately and inform a doctor.<br />To report any side effect(s):<br />Saudi Arabia<br />National Pharmacovigilance &amp; Drug Safety Centre (NPC):<br />Fax: +966-11-205-7662<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />Sanofi - Pharmacovigilance:<br />KSA_Pharmacovigilance@sanofi.com.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton and the blister pack after<br />EXP. The expiry date refers to the last day of that month.<br />Storage conditions:<br />Do not store above 25 &deg;C. Store in the original packaging to protect the contents from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Trental 400 mg contains<br />The active substance is pentoxifylline.<br />One prolonged-release tablet contains 400 mg of pentoxifylline.<br />The other ingredients are:<br />Hydroxyethyl cellulose, povidone K25, talc, magnesium stearate (Ph. Eur.) [plant origin],<br />hypromellose, titanium dioxide (E171), erythrosine (E127), macrogol 8 000.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pink, biconvex, oblong prolonged-release tablets with “ATA” engraved on one side.
Trental 400 mg is available in packs each containing 20, 50 and 100 prolonged-release tablets and as a
hospital pack of 300 prolonged-release tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder<br />sanofi-aventis Deutschland GmbH<br />65926 Frankfurt am Main, Germany</p><p>&nbsp;</p><p>Manufacturer<br />sanofi S.p.A<br />Strada Statale 17, km 22<br />I-67019 Scoppito<br />(L&rsquo;Aquila) Italy</p><p>&nbsp;</p><p>Secondary Packaging<br />Sanofiw-Aventis Arabia Co. Ltd, Kingdom of Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>المجموعة الدوائیّة العلاجیّة:<br />ترنتال ٤٠٠ ملغ ھو دواء یوصف لعلاج اضطرابات تدف قّ الدم المحیطیّة.<br />دواعي الاستعمال العلاجیّة:<br />یمكن أن تسُتعمل أقراص ترنتال ٤٠٠ ملغ المطوّلة الإطلاق لما یلي:<br />لمساعدة المرضى الذین یعانون من العرج المتقط عّ (ألم عند السیر) بسبب مرض محیطيّ شریانيّ<br />سادّ في مرحلة فونتان II للسیر لمسافات أطول في حال لا یمكن تنفیذ إجراءات علاجیّة أخرى مثل<br />العلاج الفیزیائي (التدریب على السیر) و/أو فتح الوعاء الدموي و/أو إجراءات الترمیم أو في حال لم<br />تكن ھذه الإجراءات مناسبة.<br />كعلاج لاضطرابات وظیفة الأذن الداخلیّة المتعل قّة بمشاكل دوران الدم (مثل صعوبة السمع والصمم<br />المفاجئ، إلخ...).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع الاستعمال:<br />لا تأخذ ترنتال ٤٠٠ ملغ من الحالات الآتیة:<br />إذا كنت مصابا بحساسیّة ضدّ المادة الفاعلة البنتوكسیفیلین أو ضدّ أنواع أخرى من زانثین المیثیل أو<br />أيّ من مكوّنات ترنتال ٤٠٠ الأخرى (المذكورة في القسم ٦)،<br />إذا تعرّضت لنوبة قلبیّة حادّة،<br />إذا أ صُبت بنزف في الدماغ أو بنزف آخر ذي صلة من الناحیة السریریّة (زیادة خطر النزف)،<br />إذا كنت تعاني من قرحة في المعدة و/أو في المنطقة المعویّة،<br />إذا كنت تعاني من حالات تزید من استعداد النزف.<br />إذا كنت تعاني من نزف شبكيّ (زیادة خطر النزف).<br />في حال تعرّض المریض لنزف شبكيّ في خلال مدّة العلاج بترنتال، یجب إیقاف العلاج على الفور.<br />محاذیر خاصة للاستعمال؛ تحذیرات خاصة:<br />عند الإشارات الأولى لردّة فعل تحسسیّة، یجب التوقفّ عن استعمال ترنتال على الفور وإعلام<br />الطبیب.<br />الإشراف الطبي الدقیق ضروريّ جدا لدى المرضى الذین یعانون من اضطرابات في النظم القلبيّ أو<br />من نقص ضغط الدم أو من تضیّق الأوعیة التاجیّة في القلب بعد نوبة قلبیّة أو بعد الخضوع لعملیّة<br />جراحیّة.<br />یجب استعمال ترنتال بعنایة خاصة وتحت إشراف طبيّ لدى المرضى المصابین ببعض الأمراض<br />الذاتیّة المناعة (الذأب الحمامي المجموعي وداء النسیج الضام المختلط).<br />عندما یُستعمل ترنتالبال تزامن مع أدویة تخففّ تخث رّ الدم (مضادات التخث رّ الفمویّة، مضادات<br />الفیتامین ك)، من الضروريّ إجراء رقابة دقیقة ومراقبة دائمة لقیم التخث رّ ( INR ) بسبب خطر<br />النزف.<br />المراقبة الطبیّة الدقیقة ضروریّة بشكل خاص لدى:<br />- المرضى المعالجین بالتزامن بترنتال وبمضادات السكّري الفمویّة أو بالأنسولین.<br />- المرضى المعالجین بالتزامن بترنتال وبالسیبروفلوكساسین (دواء لعلاج حالات الخمج<br />البكتیریّة).<br />یجب مراقبة التعداد الدموي بانتظام في خلال العلاج بترنتال.<br />لدى المرضى المصابین بضعف في الوظیفة الكلویّة (تصفیة الكریاتینین أقلّ من ٣٠ مل/دقیقة) أو<br />باضطرابات حادة في وظیفة الكبد، یمكن أن یتأخّر التخلصّ من البنتوكسیفیلین. في ھذه الحالات، من<br />الضروريّ تخفیض الجرعة وإجراء المراقبة المناسبة (راجع أیضًا القسم ٣).<br />الأطفال والمراھقون<br />ما من خبرة في استعمال ترنتال لدى الأطفال والمراھقین.<br />أخذ ترنتال ٤٠٠ ملغ مع أدویة أخرى</p><p>الرجاء أن تعُلم الطبیب أو الصیدلي إذا كنت تأخذ حالیّ اً أو أخذت مؤخّرًا أيّ أدویة أخرى.<br />الأدویة التي تخفضّ ضغط الدم (مضادات فرط ضغط الدم والأدویة التي قد تخفضّ ضغط الدم):<br />یمكن أن یزید ترنتال مفعول الأدویة المخفضّة لضغط الدم ومن الممكن تعرّض المریض لانخفاض<br />حاد في ضغط الدم.<br />الأدویة التي تخففّ تخث رّ الدم (مضادات التخث رّ):<br />یمكن أن یزید ترنتال مفعول مضادات التخث رّ. لدى المرضى المصابین باستعداد متزاید للنزف بسبب<br />الإعطاء المتزامن لمضاداتت خث رّ، یمكن أن تزداد خطورة أيّ نزف یحصل. فضلا عن ذلك، أفید<br />عن حالات ازدیاد تثبیط تخث رّ الدم لدى المرضى المعالجین بالتزامن بترنتال وبمضادات الفیتامین ك<br />(الكومرین). لذلك یجب أن یراقب الطبیب بدق ةّ المفعول المضاد للتخث رّ لدى ھؤلاء المرضى (مثلاً<br />فحوصات INR منتظمة)، بخاصة عند البدء بالعلاج بترنتال أو عند تعدیل الجرعة.<br />مضادات السكّري الفمویّة (أدویة علاج داء السكّري)، الأنسولین:<br />یمكن أن یزداد المفعول المدنيّ لسكّر الدم (نقص سكّر الدم) لھذه الأدویة. یجب مراقبة مستویات سكّر<br />الدم على فترات فاصلة محدّدة حسب كلّ حالة.<br />الثیوفیلین (دواء لعلاج الأمراض التنف سّیة):<br />من المحتمل أن تزداد معدّلات الثیوفیلین في الدم وبالتالي یمكن أن تزداد التأثیرات الجانبیّة للثیوفیلین<br />في خلال فترة علاج الأمراض التنفسیّة.<br />السیمیتیدین (دواء یخفضّ الحمض المعدي):<br />من الممكن حصول زیادة في معدّ لات البنتوكسیفیلین في البلازما وزیادة مفعول ترنتال.<br />السیبروفلوكساسین (دواء لعلاج حالات الخمج البكتیریّة):<br />یمكن أن یزید الاستعمال المتزامن لترنتال والسیبروفلوكساسین تركیزات البنتكسیفیلین في المصل<br />لدى بعض المرضى. ولذلك، یمكن أن یزید الاستعمال المتزامن لھذه الأدویة عدد التأثیرات الجانبیّة<br />وحدّتھا.<br />الحمل والإرضاع<br />إذا كنتِ حاملا أو مرضعة، أو كنتِ تعتقدین نفسكِ حاملا أو كنتِ تنوین الحمل، استشیري طبیبك قبل<br />أخذ ھذا الدواء.<br />یُمنع استعمال ترنتال ٤٠٠ ملغ في خلال فترة الحمل بسبب نقص التجارب لدى النساء الحوامل.<br />دلى النساء المرضعات، ینتقل البنتوكسیفیلین إلى حلیب الثدي، لكنّ الطفل الرضیع لا یتلق ىّ إلا كمیّات<br />صغیرة جدا من المادة الفاعلة بالتالي من غیر المتوق عّ أن یتعرّض الطفل الرضیع لأيّ تأثیرات في<br />خلال فترة الإرضاع عندما یُستعمل الدواء كما یجب. قبل استعمال ترنتال لدى النساء المرضعات،<br />یجب أن یُجري الطبیب تقییمًا دقیق اً للمنفعة والخطر.<br />قیادة السیّارات واستعمال الآلات</p><p>ما من تأثیرات معروفة على القدرة على القیادة واستعمال الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>مقدار الجرعة:<br />خذ دائمًا ھذا الدواء حسب وصفة الطبیب تمامً ا. في حال الشكّ الرجاء أن تسأل الطبیب أو الصیدلي.<br />العرج المتقط عّ بسبب مرض محیطيّ شریانيّ سادّ في مرحلة فونتان IIb<br />إلا في حال وصف الطبیب غیر ذلك، یجب علیك تناول قرص واحد من ترنتال ٤٠٠ ملغ المطوّل<br />الإطلاق ٣ مرّات في الیوم (أيّ ما یعادل ١٢٠٠ ملغ من البنتوكسیفیلین في الیوم).<br />الاضطرابات الوظیفیة للأذن الداخلیّة المتعل قّة بدفق الدم (مثل صعوبة السمع والصمم المفاجئ،<br />إلخ...)<br />إلا في حال وصف الطبیب غیر ذلك، تبلغ الجرعة العادیّة قرصًا واحدًا من ترنتال ٤٠٠ ملغ المطوّل<br />الإطلاق مرّتین أو ٣ مرّات في الیوم (أيّ من ٨٠٠ إلى ١٢٠٠ ملغ من البنتوكسیفیلین في الیوم).<br />ضغط دم منخفض أو اضطرابات دوران الدم:<br />قد یكون من الضروريّ إعطاء تعلیمات خاصة بمعایرة الجرعات لدى المرضى الذین یكون ضغط<br />الدم لدیھم منخفضًا أو لدى المرضى الذین یعانون من اضطرابات في دوران الدم.<br />ضعف في الوظیفة الكلویّة (تصفیة الكریاتینین أقلّ من ٣٠ مل/دقیقة):<br />یجب ضبط الجرعة حسب قدرة التحمّل الفردیّة لدى المرضى الذین یعانون من ضعف في الوظیفة<br />الكلویّة.<br />اضطرابات حادة في الوظیفة الكبدیّة:<br />یجب تخفیض الجرعة لدى المرضى الذین یعانون من اضطرابات حادة في وظیفة الكبد. سوف یحدّد<br />الطبیب الجرعة المخفضّة على أساس فرديّ حسب حدّة الاضطراب وقدرة التحمّل الفردیّة.<br />طریقة التناول ومدّة العلاج:<br />ابلع الأقراص المطوّلة الإطلاق كاملة بعد الطعام مع كمیّة كافیة من الماء (مثلا كوب من الماء).<br />سوف یحدّد الطبیب المعالج مدّة العلاج.<br />ملاحظة:<br />في حالات العبور المعدي المعوي السریع (دواء ملیّن، إسھال، تقصیر المعى عن طریق الجراحة،<br />إلخ.)، وجد بعض المرضى بقایا الأقراص في البراز في حالات نادرة جدًّ ا. یجب علیك استشارة<br />الطبیب في ھذه الحالة.<br />إذا أخذت جرعة زائدة من ترنتال ٤٠٠ ملغ</p><p>قد تظھر العلامات والعوارض الآتیة بعد استعمال جرعة مفرطة من ترنتال ٤٠٠ ملغ عن طریق<br />الخطأ أو عمدًا : دوار، غثیان، ھبوط في ضغط الدم، تسرّع القلب، احمرار الوجھ مع شعور بالحرّ<br />(تورّد)، فقدان الوعي، حمّى، تململ، غیاب ردّات الفعل، نوبات توتّریة-ارتجافیّة، قيء كتفل القھوة<br />واضطرابات في النظم القلبي.<br />في حال تناول جرعة مفرطة أعلم الطبیب أو طبیب طوارئ على الفور وسوف یقرّر الإجراءات<br />التي یجب اتخاذھا.<br />إذا نسیت أخذ ترنتال ٤٠٠ ملغ<br />إذا نسیت أخذ جرعة، لا تأخذ جرعة مضاعفة من ترنتال في المرّة القادمة ولكن تابع العلاج حسب<br />تعلیمات مقدار الجرعة أو حسب وصفة الطبیب.<br />إذا توق فّت عن أخذ ترنتال ٤٠٠ ملغ<br />لا یجدر بك قطع العلاج بترنتال ٤٠٠ ملغ أو إیقافھ بدون استشارة الطبیب أوّلا .ً<br />إذا كان لدیك أسئلة إضافیّة حول استعمال ھذا الدواء، إطرحھا على الطبیب أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل ادلأویة كل ھّا، قد یسبّب ھذا الدواء تأثیرات جانبیّة لا تصُیب المرضى كل ھّم.<br />تسُتعمل الفئات الآتیة لتحدید معدّل حصول التأثیرات الجانبیّة:<br />التأثیرات الشائعة جدّ اً: أكثر من مریض من أصل ١٠ مرضى معالجین.<br />التأثیرات الشائعة: من مریض إلى ١٠ مرضى من أصل ١٠٠ مریض معالج.<br />التأثیرات غیر الشائعة: من مریض إلى ١٠ مرضى من أصل ١٠٠٠ مریض معالج.<br />التأثیرات النادرة: من مریض إلى ١٠ مرضى من أصل ١٠٠٠٠ مریض معالج.<br />التأثیرات النادرة جدّ اً: أقلّ من مریض من أصل ١٠٠٠٠ مریض معالج<br />التأثیرات غیر المعروفة: لا یمكن تقدیر معدّل حصولھا استنادًا إلى المعطیات المتوافرة.<br />التأثیرات الجانبیّة المحتملة<br />الدم<br />التأثیرات النادرة جدا :ً انخفاض عدد الصفیحات الدمویّة مع نزف تحت الجلد (فرفریّة انحلال<br />الصفیحات) وفي بعض الحالات انخفاض أو غیاب تشكّل كل الخلایا الدمویّة.<br />لذا یجب إجراء التعداد الدموي بانتظام.<br />جھاز المناعة/فرط الحساسیّة<br />التأثیرات غیر الشائعة: فرط حساسیّة جلدیّة (راجع فقرة التأثیرات على الجلد).<br />التأثیرات النادرة جدًّ ا: فرط حساسیّة حاد یحصل في غضون دقائق من تناول ترنتال مثل تورّم<br />الأغشیة الجلدیّة والمخاطیّة (خزب وعائي) تشن جّ العضلات القصبیّة وقصور دوراني (صدمة<br />إستھدافیّة).<br />عند الإشارات الأولى لفرط الحساسیّة، یجب إیقاف العلاج بترنتال على الفور وإعلام الطبیب.</p><p>الاضطرابات العقلیّة<br />التأثیرات غیر الشائعة: تململ، اضطرابات في النوم.<br />الجھاز العصبي<br />التأثیرات غیر الشائعة: دوار، رجفة، صداع.<br />التأثیرات النادرة جدًّ ا: الشعور بخدر وببرودة في الأطراف (تنمّل)، نوبات صرع (إختلاجات)، نزف<br />في الجمجمة. یمكن حصول عوارض التھاب غیر متعل قّ بخمج في بطانة الدماغ.<br />یبدو أن لدى المرضى المصابین بأمراض ذاتیّة المناعة (مثلا الذأب الحمامي المجموعي أو داء<br />النسیج الضام المختلط) استعداد كبیر للإصابة بھذا النوع من التأثیرات. في كلّ الحالات اختفت<br />العوارض بعد إیقاف ترنتال.<br />العینان<br />التأثیرات غیر الشائعة: اضطرابات بصریّة، التھاب الملتحمة.<br />التأثیرات النادرة جدًّ ا: نزف شبكي، انفصال الشبكیّة.<br />في حال حصول نزف شبكيّ في خلال مدّة العلاج، یجب إیقاف العلاج بترنتال على الفور.<br />القلب<br />التأثیرات غیر الشائعة: اضطرابات في النظم القلبيّ مثل تسارع دق اّت القلب.<br />التأثیرات النادرة: شعور بضیق في الصدر (ذبحة صدریّة) وبضیق نفس.<br />الأوعیة الدمویّة<br />التأثیرات النادرة: احمرار الوجھ مع شعور بالحرّ (تورّد).<br />التأثیرات النادرة: نزف (راجع فقرة التأثیرات الجانبیّة للأعضاء المختلفة).<br />الجھاز الھضمي<br />التأثیرات الشائعة: اضطرابات معدیّة معویّة مثل الغثیان والتقیّؤ والشعور بالنفخة والثقل في المعدة<br />والإسھال.<br />التأثیرات النادرة: نزف معدي ومعوي.<br />الكبد والمرارة<br />التأثیرات النادرة جدًّ ا: انسداد سائل المرّة في الكبد، زیادة في قیم الفحوصات الكبدیّة (راجع فقرة<br />الاستقصاءات).<br />الجلد<br />التأثیرات النادرة جدًّ ا: حكّة، احمرار الجلد، شرى.<br />التأثیرات النادرة: نزف في الغشاء الجلدي والمخاطي.<br />التأثیرات النادرة جدًّ ا: ارتكاسات جلدیّة خطیرة (نكروز بشروي، تناذر ستیفنز- جونسون)، تعرّق.</p><p>الكلى والمسالك البولیّة<br />التأثیرات النادرة: نزف في محیط الأعضاء البولیّة والتناسلیّة.<br />الاستقصاءات<br />التأثیرات النادرة: انخفاض ضغط الدم.<br />التأثیرات النادرة جدًّ ا: زیادة قیم الفحوصات الكبدیّة، ارتفاع ضغط الدم.<br />الاضطرابات العامة<br />التأثیرات غیر الشائعة: حمّى.<br />التأثیرات النادرة: تراكم السائل في الأنسجة (مثلا في الذراعین والساقین).<br />ملاحظة:<br />یمكن أن یكون ضیق النفس والتقیّؤ والتعرّق والدوار عبارة عن إشارات مبكرة تدلّ على فرط<br />الحساسیّة. في ھذه الحالات، توقفّ عن تناول ترنتال ٤٠٠ ملغ على الفور واتصل بالطبیب.<br />الإفادة عن التأثیرات الجانبیّة<br />في حال تفاقم أحد التأثیرات الجانبیّة أو في حال لاحظت تأثیرات جانبیّة غیر مذكورة في ھذه النشرة،<br />الرجاء أن تعُلم الطبیب أو الصیدلي. بالإفادة عن التأثیرات الجانبیّة، یمكنك المساعدة على تزوید<br />المزید من المعلومات حول سلامة ھذا الدواء.<br />للإبلاغ عن الأعراض الجانبی ة<br />المملكة العربیة السعودیة<br />المركز الوطني للتیقظ والسلامة الدوائیة:<br />فاكس: ٠٠٩٦٦١١٢٠٥٧٦٦٢<br />الھاتف المجاني: ٨٠٠٢٤٩٠٠٠٠<br />البرید الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: www.sfda.gov.sa/npc<br />سانوفي-التیقظ الدوائي:<br />KSA_Pharmacovigilance@sanofi.com</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحفظ الدواء بعیدًا عن متناول الأطفال ونظرھم.<br />لا تأخذ ھذا الدواء بعد انقضاء تاریخ الصلاحیّة المدوّن على العلبة والظرف بعد كلمة EXP . یشیر<br />تاریخ انتھاء الصلاحیّة إلى الیوم الأخیر من الشھر المذكور.<br />شروط الحفظ:<br />لا تحفظ الدواء في درجة حرارة تفوق ٢٥ درجة مئویّة. احفظ الدواء في علبتھ الأصلیّة لحمایة<br />المحتویات من الرطوبة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماذا یحتوي ترنتال ٤٠٠ ملغ<br />المادة الفاعلة ھي البنتوكسیفیلین.<br />یحتوي كلّ قرص مطوّل الإطلاق على ٤٠٠ ملغ من البنتوكسیفیلین.<br />المكوّنات الأخرى ھي: سلولوز ھیدروكسید الإیثیل، بوفیدون ك ٢٥ ، طلق، ستیارات المغنیزیوم<br />Ph. Eur.) ) [من أصل نباتيّ]، ھیبروملوز، ثاني أكسید التیتانیوم (إي ١٧١ )، إیریثروزین (إي<br />١٢٧ )، ماكروغول ٨٠٠٠ .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">كیف ھو شكل ترنتال ٤٠٠ ملغ وما ھي محتویات العلبة<br />أقراص زھریّة اللون ثنائیّة التحدّب مستطیلة مطوّلة الإطلاق، مختومة على جھة منھا &rdquo; . &ldquo;ATA<br />یأتي ترنتال ٤٠٠ ملغ في علب یحتوي كلّ منھا على ٢٠ أو ٥٠ أو ١٠٠ قرص مطوّل الإطلاق وفي<br />علبة مخصصة للمستشفیات من ٣٠٠ قرص مطوّل الإطلاق.<br />قد لا تكون أحجام العلب كل ھّا مسوّقة في بلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة حاملة رخصة التسویق<br />sanofi-aventis Deutschland GmbH<br />65926 Frankfurt am Main, Germany</p><p>&nbsp;</p><p>الشركة المصن عّة<br />Sanofi S.p.A<br />Strada Statale 17, km 22<br />I-67019 Scoppito (L&rsquo;Aquila)<br />Italy</p><p>&nbsp;</p><p>التغلیف الثانوي:<br />شركة سانوفي-أفنتیس العربیة لیمیتد<br />المملكة العربیة السعودیة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            حزیران ٢٠١٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trental® 400 mg
Prolonged-release tablets
Active substance: pentoxifylline
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 prolonged-release tablet contains 400 mg pentoxifylline.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release tablet.
Pink, biconvex, oblong, prolonged-release tablet with the inscription “ATA” on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prolongation of walking distance in patients with chronic peripheral arterial occlusive disease at Fontaine stage IIb (intermittent claudication) if<br />other measures such as walking training, angioplasty and/or reconstructive procedures cannot be performed or are not indicated.<br />Inner ear dysfunction caused by circulatory disorders (including hardness of hearing, sudden hearing loss).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Chronic peripheral arterial occlusive disease at Fontaine stage IIb (intermittent claudication)<br />Unless otherwise prescribed, 1 Trental 400 mg prolonged-release tablet three times daily (equivalent to 1,200 mg pentoxifylline per day).<br />Special dosage instructions may be necessary for patients with low or fluctuating blood pressure levels.<br />In patients with impaired renal function (creatinine clearance less than 30 ml/min), the dose should be adjusted according to individual tolerability.<br />In the case of patients with severe hepatic dysfunction, a dose reduction is required, which should be decided by the doctor on an individual<br />basis according to the severity of the illness and tolerability.<br />Inner ear dysfunction caused by circulatory disorders (including hardness of hearing, sudden hearing loss).<br />Unless otherwise prescribed, 1 Trental 400 mg prolonged-release tablet twice daily or three times a day (equivalent to 800&ndash;1,200 mg<br />pentoxifylline per day).<br />In cases of severe circulatory disturbances, a combination with parenterally administered Trental 100 mg or 300 mg ampoules (IV infusion) can<br />accelerate the onset of action. The total daily dose (parenteral + oral) should essentially not exceed 1,200 mg pentoxifylline.<br />Depending on the severity of symptoms, oral-only treatment, combined oral-parenteral treatment (IV infusion) or parenteral-only treatment (IV<br />infusion) can be administered.<br />For patients with low or fluctuating blood pressure values, special dosage instructions may be required.<br />In patients with impaired renal function (creatinine clearance less than 30 ml/min), the dose should be titrated to 50&ndash;70% of the standard dose,<br />depending on individual tolerability, e.g. by taking 400 mg pentoxifylline twice daily instead of 400 mg pentoxifylline three times a day.<br />In patients with severe hepatic dysfunction, a dose reduction is required, which should be decided by the doctor on an individual basis according<br />to the severity of illness and patient tolerability.<br />Children and adolscents<br />No experience is available concerning the use of Trental in children and adolescents<br />Method and duration of administration<br />The prolonged-release tablets should be swallowed whole (without chewing) with plenty of liquid following a meal. Duration of use must be<br />tailored to the individual clinical condition and is decided by the doctor.<br />Note<br />In the case of accelerated gastro-intestinal passage (laxatives, diarrhoea, surgical shortening of the intestine), elimination of tablet residues can<br />occur in isolated cases. If premature elimination occurs only now and again, no importance need be attributed to the process.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trental 400 mg must not be used in the following cases:
- hypersensitivity to the active substance pentoxifylline, other methylxanthines or to any of the excipients of Trental 400 mg listed in section
6.1,
- acute myocardial infarction,
- intracerebral bleeding or other clinically relevant bleeding (increased risk of haemorrhage),
- gastric and/or intestinal ulcers,
- bleeding diathesis,
- retinal haemorrhages (increased risk of bleeding).
If retinal haemorrhages occur during treatment with pentoxifylline, use of the medicinal product must be discontinued at once.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At the first signs of a hypersensitivity reaction, the medicinal product must be discontinued immediately and the doctor informed.<br />Particularly close medical supervision is necessary in patients with cardiac arrhythmias, hypotension, coronary sclerosis, following a heart attack<br />or postoperatively following surgical interventions.<br />In patients with systemic lupus erythematosus (SLE) or mixed connective tissue disease, pentoxifylline should only be used after careful<br />assessment of the risks and benefits.<br />Owing to the risk of haemorrhage, close supervision and frequent checks of the coagulation parameters (INR) are required during concomitant<br />use of pentoxifylline and oral anticoagulants (vitamin K antagonists) (see also section 4.5).<br />Particularly careful monitoring is required:<br /> in patients treated concomitantly with pentoxifylline and oral antidiabetics or insulin(see also section 4.5),<br /> in patients treated concomitantly with pentoxyfylline and ciprofloxacin (see also section 4.5).<br />Due to the risk of aplastic anaemia during treatment with pentoxifylline, the blood count should be regularly monitored.<br />Elimination of pentoxifylline may be delayed in patients with impaired renal function (creatinine clearance less than 30 ml/min) or severe hepatic<br />dysfunction. Appropriate monitoring is required.<br />Patients with impaired renal function:<br />In patients with impaired renal function (creatinine clearance less than 30 ml/min), the dose should be adjusted to 50-70% of the standard dose<br />depending on individual tolerability, e.g. by taking 400 mg pentoxifylline twice daily instead of 400 mg pentoxifylline three times a day.<br />Patients with severe liver dysfunction:<br />In the case of patients with severe hepatic dysfunction, a dose reduction is required, which should be decided by the doctor on an individual<br />basis according to the severity of the illness and tolerability.<br />Immediate measures in the event of severe hypersensitivity reactions (shock):<br />At the first signs (e.g. skin reactions such as urticaria, flushing, restlessness, headaches, outbreaks of sweating, nausea), establish a venous<br />access. As well as the usual emergency measures, i.e. placing the patient in a supine position with the legs raised, keeping the airways clear and<br />administering oxygen, immediate medication such as intravenous volume replacement, epinephrine (adrenaline) IV, glucocorticoids (e.g. 250-<br />1,000 mg methylprednisolone IV) and histamine receptor antagonists is indicated.<br />Depending on the severity of the clinical symptoms, artificial respiration and, in the event of circulatory arrest, resuscitation in accordance with<br />the usual recommendations may be required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following interactions of this medicinal product must be taken into account:<br />Antihypertensives<br />Pentoxifylline may increase the effect of antihypertensives or medications with a hypotensive potential: the decrease in blood pressure may be<br />intensified.<br />Anticoagulants<br />Pentoxifylline may increase the effect of anticoagulants. In patients with an increased bleeding tendency due to concomitant use of anticoagulant<br />medications, any bleeding that occurs may be increased. Furthermore, cases of increased anticoagulation have been reported in patients<br />receiving concomitant treatment with pentoxifylline and vitamin K antagonists (coumarins). Therefore, careful monitoring of the anticoagulant<br />effect is recommended in such patients (e.g. by regular checks on INR), especially when therapy with pentoxifylline is initiated or the dosage<br />changed.<br />Oral antidiabetics, insulin<br />There may be a more pronounced decrease in blood sugar, causing hypoglycaemic reactions. Glycaemic control should be monitored at<br />intervals determined on a case-by-case basis.<br />Theophylline<br />Raised blood levels of theophylline are possible, so that undesirable effects of theophylline may be exacerbated during the treatment of<br />respiratory diseases.<br />Cimetidine<br />Raised plasma levels of pentoxifylline and an increased effect of pentoxifylline are possible.<br />Ciprofloxacin</p><p>Concomitant administration with ciprofloxacin may increase the serum concentration of pentoxifylline in some patients. Therefore, there may be<br />an increase in and intensification of adverse reactions associated with co-administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pentoxifylline should not be taken during pregnancy because there has been insufficient experience of its use in pregnant women (see also<br />section 5.3).<br />During lactation, pentoxifylline passes into breast milk. However, the infant receives only minute amounts of the active substance. Therefore the<br />indicated use of pentoxifylline during lactation is unlikely to have any effect on the infant. Prior to administering pentoxifylline in breast-feeding<br />women, a careful benefit-risk assessment by the doctor is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No effects on the ability to drive and operate machinery have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects, which have been reported in clinical studies or during post-marketing, can occur during treatment with Trental<br />400 mg.<br />The following categories are used for stating the frequency of undesirable effects:<br />Very common ( 1/10)<br />Common ( 1/100 to &lt; 1/10)<br />Uncommon ( 1/1,000 to &lt; 1/100)<br />Rare ( 1/10,000 to &lt; 1/1,000)<br />Very rare (&lt; 1/10,000)<br />Not known (cannot be estimated from the available data)<br />Blood and lymphatic system disorders<br />Very rare: thrombocytopenia with thrombocytopenic purpura and possibly fatal aplastic anaemia (pancytopenia).<br />For this reason, the blood picture should be regularly monitored.<br />Immune system disorders<br />Uncommon: cutaneous hypersensitivity reactions (see Undesirable effects of the skin).<br />Very rare: severe anaphylactic or anaphylactoid reactions developing within minutes of pentoxifylline administration, such as angioedema,<br />bronchospasm, anaphylactic shock.<br />At the first signs of a hypersensitivity reaction, the medicinal product must be discontinued immediately and the doctor informed.<br />Psychiatric disorders<br />Uncommon: agitation, sleep disturbances.<br />Nervous system disorders<br />Uncommon: dizziness, tremor, headache.<br />Very rare: paraesthesia, convulsions, intracranial bleeding. Symptoms of aseptic meningitis: patients with autoimmune diseases (SLE, mixed<br />connective tissue disease) appear to be prone to these symptoms. In all observed cases, the symptoms were reversible upon discontinuation of<br />pentoxifylline.<br />Eye disorders<br />Uncommon: visual disturbances, conjunctivitis.<br />Very rare: retinal haemorrhage, detachment of the retina.<br />If retinal haemorrhage occurs during treatment with pentoxifylline, the medicinal product must be discontinued immediately.<br />Cardiac disorders<br />Uncommon: cardiac arrhythmia, e.g. tachycardia.<br />Rare: angina pectoris, dyspnoea.<br />Vascular disorders<br />Common: flushing.<br />Rare: bleeding (see undesirable effects on various organs).<br />Gastrointestinal disorders<br />Common: gastrointestinal complaints, such as nausea, vomiting, bloatedness, pressure in the stomach, diarrhoea.<br />Rare: gastric and intestinal bleeding.<br />Hepatobiliary disorders<br />Very rare: intrahepatic cholestasis, elevation of liver enzymes (see Investigations).<br />Skin and subcutaneous tissue disorders<br />Uncommon: pruritus, erythema, urticaria.<br />Rare: mucocutaneous bleeding.<br />Very rare: epidermal necrolysis, Stevens-Johnson syndrome, sweating.<br />Renal and urinary disorders<br />Rare: urogenital bleeding.<br />Investigations</p><p>Rare: decreased blood pressure.<br />Very rare: increase in transaminases or alkaline phosphatases, elevated blood pressure.<br />General disorders<br />Uncommon: fever.<br />Rare: peripheral oedema.<br />For reporting any side effects please contact KSA<br />The National Pharmacovigilance and Drug Safety Center (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340<br />Toll free phone: 8002490000<br />&bull; Email: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc<br />KSA_pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Dizziness, nausea, blood pressure decrease, tachycardia, flushing, loss of consciousness, fever, agitation, areflexia, tonic-clonic convulsions,<br />coffee-ground vomit and arrhythmias.<br />Therapeutic measures<br />If the overdose has happened recently, gastric lavage can be performed or further absorption can be delayed by the use of activated charcoal.<br />Treatment should be symptomatic since there is no known specific antidote. Observation under intensive care conditions may be necessary to<br />avoid complications.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Peripheral vasodilators, purine derivatives.<br />ATC code: C04AD03<br />Pentoxifylline improves the flow properties of blood by lowering the elevated blood viscosity and possesses further pharmacological properties<br />which are explained by the fact that it:<br />- increases impaired red cell deformability by inhibiting phosphodiesterase with a subsequent increase in intracellular cAMP and ATP and by<br />inhibiting red cell aggregation<br />- inhibits platelet aggregation<br />- lowers pathologically raised plasma fibrinogen levels<br />- inhibits leucocyte activation and the adhesion of leucocytes to the vascular endothelium.<br />Studies investigating the effect of pentoxifylline on cardio- and cerebrovascular morbidity and/or mortality are not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pentoxifylline undergoes prolonged release from Trental 400 mg over 10-12 hours so that constant blood levels are maintained during this<br />period. The released pentoxifylline is rapidly and almost completely absorbed. The substance undergoes a marked first-pass effect so that the<br />systemic availability is only 20-30%.<br />Pentoxifylline is metabolised almost entirely in the liver. The active main metabolite 1-(5-hydroxyhexyl)-3,7-dimethylxanthine (metabolite I) is<br />measurable in plasma at a concentration twice that of the parent substance, with which it is in reversible biochemical equilibrium. Pentoxifylline<br />and metabolite I are therefore regarded as the active unit. Pentoxifylline undergoes biphasic elimination; the initial half-life of the parent<br />substance is 0.4-0.8 h, that of the metabolites 1.0-1.6 h. The terminal plasma half-life of pentoxifylline is given as approx. 1.6 hours.<br />Elimination is largely renal in the form of water-soluble polar metabolites without conjugation; only 4% is eliminated with the faeces. Unchanged<br />pentoxifylline is only excreted in traces.<br />Metabolite excretion is delayed in patients with severely impaired renal function.<br />In patients with hepatic dysfunction, the elimination half-life is prolonged and absolute bioavailability is increased (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In human subjects, oral doses of 80 mg/kg body weight produced the signs of overdosage listed in section 4.9 (q.v.).<br />In chronic toxicity studies, no substance-related toxic organ damage was detected after feeding with pentoxifylline for one year at doses of up to<br />1,000 mg/kg BW daily in rats and up to 100 mg/kg BW daily in dogs. Lack of coordination, circulatory failure, haemorrhages, pulmonary oedema<br />and giant cells in the testes were determined in isolated dogs receiving daily dosages of 320 mg/kg BW or above for one year.<br />Mutagenicity studies with pentoxifylline revealed no relevant evidence of mutagenic effects. The results of long-term studies of carcinogenic<br />potential in mice and rats were negative.</p><p>Reproduction toxicity studies were performed on rats, mice, rabbits and dogs. There was no evidence of any teratogenic damage, embryotoxicity<br />or effect on fertility. An increased absorption rate was observed with very high doses.<br />Pentoxifylline and its metabolites pass into breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydroxyethyl cellulose, povidone K 25, talc, magnesium stearate (Ph.Eur.) [plant-based], hypromellose, titanium dioxide (E171), erythrosine<br />(E127), macrogol 8000.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known to date.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C. Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister<br />Pack sizes:<br />Packs of<br />20 prolonged-release tablets<br />100 prolonged-release tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sanofi-Aventis Deutschland GmbH
D-65926 Frankfurt am Main
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>